logo/base Created with Sketch.

Agile 3+

Identification of advanced fibrosis in MASLD patients.

Agile 3+ is a FibroScan®-based score


Agile 3+ Target

Although NAFLD is the most common chronic liver disease worldwide, early intervention can reverse liver damage and improve patient outcomes.

Identifying patients with advanced fibrosis (F≥3 according to NASH CRN scoring system) is key for the management of patients with MASFD since they are at increased risk of developing liver-related complications.

Agile 3+ Construction

Agile 3+ combines LSM by VCTE™  with easily accessible blood biomarkers (AST, ALT, Platelets) to help in the identification of advanced fibrosis in MASLD patients with optimized Positive Predictive values compared to LSM alone and help in the prediction of liver complications.


formule agile3


Agile 3+ Performance

High clinical performances demonstrated in large external validation cohorts from different geographical origins.

agile 3+ - echosens clinical validation


Peer reviewed paper under submission
Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease patients with FibroScan®-based Agile scores

Agile 3+: tried and trusted


A novel noninvasive score including LSM by VCTE™ and routine clinical parameters improves the identification of advanced fibrosis among patients with MASLD and may reduce the necessity of liver biopsy in this patient population. In addition, external validation on primary and secondary care centers could assess its potential as a new tool to refer patients to liver specialists.

A.J. Sanyal et all. | ILC 2021


Agile 3+ and Agile 4 well predict the occurrence of liverrelated events in patients with MASLD. Particularly, rule-in cut-offs of both scores better identify at-risk patients than LSM alone. These results demonstrate the interest of those scores in the identification of patients requiring hepatocellular carcinoma and esophageal varices screening.

J. Boursier et all. | ILC 2021

chevron chevron

Webinar: Agile 3+ presented at ILC 2021

Agile 3+ is a registered class 1 device (FDA). Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of MASLD as having advanced fibrosis. It was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Agile 3+ is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and health issues, it is not a substitute for or a replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.

*MASLD/MASH is formerly knowed as NAFLD/NASH